These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 7208342)

  • 1. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
    Micheli H; Pometta D; Gustafson A
    Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II].
    Chojnowska-Jezierska J; Jabłoński S; Tkaczewski W
    Wiad Lek; 1993 May; 46(9-10):332-6. PubMed ID: 8236987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M; Bonnefous F; Debbas N; Irvine A
    Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen.
    Micheli H; Pometta D; Gustafson A
    Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):503-6. PubMed ID: 528097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
    Feussner G; Kurth B; Lohrmann J
    Eur J Med Res; 1997 Apr; 2(4):165-8. PubMed ID: 9110923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
    Artery; 1985; 12(6):363-81. PubMed ID: 4051756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacology of fenofibrate (author's transl)].
    Kritchevsky D
    Nouv Presse Med; 1980 Dec; 9(49):3769-73. PubMed ID: 7208345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
    Koanantakul B; Jeamanukulkit N; Piamsomboon C; Chawantanpipat C; Khanacharoen I
    J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of fenofibrate in various types of hyperlipoproteinemias].
    Sucić M
    Lijec Vjesn; 1989 Mar; 111(3):93-7. PubMed ID: 2747411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of procetofen on serum lipids and apoproteins.
    Capurso A; Mogavero AM; Taverniti R; Resta F; Pace L; Bonomo L
    Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):194-7. PubMed ID: 6715088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.